LB Pharmaceuticals Launches $100 Million IPO Effort (Pending:LBRX)

LB Pharmaceuticals plans a $100M IPO to fund Phase 3 trials for its schizophrenia drug LB-102, targeting a growing market. Learn more on LBRX stock here.